These results indicate that the combination of an SGK1 or NF-κB inhibitor and bortezomib or ixazomib may be a potential therapy for MM harboring the overexpression and activation of the SGK1/NF-κB pathway. This evidence concerns the gene NFKB1 and Miyoshi myopathy.